More on ARTL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.55 |
|
|||
| Open | $2.54 | ||||
| 52 Wk High | $6.22 | ||||
| 52 Wk Low | $2.74 | ||||
| Day High | $2.54 | ||||
| Day Low | $2.15 | ||||
| P/E | N/A | ||||
| EPS | $-0.21 | ||||
| Volume | 169,403 | ||||
- Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
- Form 8-K ARTELO BIOSCIENCES, INC. For: Oct 09
- Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
- Artelo files patent for ART27.13 in obesity, including GLP-1 combo
- Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
- Artelo's ART27.13 matches semaglutide weight loss in mouse study
- Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
- Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26
- Artelo Biosciences executes 1-for-9 reverse stock split
- Artelo Biosciences Announces Reverse Stock Split
Entities mentioned with ARTL
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- Show More...
